Jack Corrigan and Vikram Venkatram shared their expert analysis in an op-ed published by The National Interest. In their piece, they examine the political and legal controversy surrounding the Biden administration’s draft guidance on “march-in rights” under the Bayh-Dole Act, which could allow federal agencies to lower drug prices by reclaiming patents on taxpayer-funded inventions when they are not reasonably accessible to the public.
Corrigan and Venkatram emphasized the importance of aligning public research with public benefit, noting, “Excluding price from march-in considerations would give private companies near-total control over the terms on which the American people can benefit from the inventions their tax dollars helped create.”
Excluding price from march-in considerations would give private companies near-total control over the terms on which the American people can benefit from the inventions their tax dollars helped create.Jack Corrigan and Vikram Venkatram
To read the full op-ed, visit The National Interest.